Illumina, Inc. stock performance trend indicates that the stock price has rallied 24.6% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -11.69% . Looking at the past 52 week period, the stock price is up at 6.78% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Illumina, Inc. has a positive value of 18.6 compared to overall market.Illumina, Inc. is having a Relative Strength Index of 41.34 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Illumina, Inc. (NASDAQ:ILMN) has tumbled 4.07% during the past week and has dropped 1.81% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 4.29%. Illumina, Inc. (NASDAQ:ILMN) has underperformed the index by 2.92% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Company shares have received an average consensus rating of Hold for the current week Illumina, Inc. (NASDAQ:ILMN) : On Friday heightened volatility was witnessed in Illumina, Inc. (NASDAQ:ILMN) which led to swings in the share price. The stock opened for trading at $159 and hit $161.79 on the upside , eventually ending the session at $160.42, with a gain of 0.6% or 0.96 points. The heightened volatility saw the trading volume jump to 1,917,751 shares. The 52-week high of the share price is $186.88 and the company has a market cap of $23,469 million. The 52-week low of the share price is at $119.37 .
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by UBS on Feb 1, 2017 to Buy, Raises Price Target to $ 185 from a previous price target of $180 .Illumina was Initiated by Deutsche Bank on Jan 18, 2017 to Hold, Price Target of the shares are set at $160.Illumina was Upgraded by BofA/Merrill to Buy on Jan 10, 2017. Illumina was Upgraded by CL King to Buy on Jan 6, 2017.
Company has reported several Insider transactions to the SEC, on Mar 10, 2017, A Blaine Bowman (director) sold 3,000 shares at 165.12 per share price.On Feb 21, 2017, Daniel Bradbury (director) sold 600 shares at 162.79 per share price.On Feb 15, 2017, Omead Ostadan (EVP Ops, Products, Strategy) sold 2,173 shares at 163.10 per share price.
Illumina Last issued its quarterly earnings results on Jan 31, 2017. The company reported $0.85 EPS for the quarter, beating the analyst consensus estimate by $ 0.02. Analyst had a consensus of $0.83. The company had revenue of $619.00 million for the quarter, compared to analysts expectations of $614.41 million. The companys revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.81 EPS.
Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The companys tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.